Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

62
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
62
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

62
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
62
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

421
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
421
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

74
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
74
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

100
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
100
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

81
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
81

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Disparities in Healthcare Access and Treatment Outcomes for Patients with Chronic Limb-Threatening Ischemia.

Current problems in cardiology·2026
Same author

Outcomes of Percutaneous Coronary Intervention Stratified by Body Mass Index.

Cureus·2026
Same author

Using Patient Feedback to Improve Treatment Outcomes for Patients with Congenital Dyserythropoietic Anaemia Type I Receiving Interferon Therapy.

Journal of clinical medicine·2026
Same author

SHARK: A Specialized Host for Assembling R6K Plasmids.

ACS synthetic biology·2026
Same author

Emerging trends in genome integration tools for precision engineering of diverse bacterial species.

Synthetic biology (Oxford, England)·2026
Same author

The Influence of Race, Ethnicity and Historical Redlining on Psoriatic Disease Burden and Clinical Outcomes.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same journal

Implantable Cardioverter-Defibrillator in Cardiac Sarcoidosis: A Propensity-Score Matched Analysis.

Current problems in cardiology·2026
Same journal

Arterial Stiffness in Heart Failure with Preserved Ejection Fraction: is this a new Predisposing Factor?

Current problems in cardiology·2026
Same journal

The Future of Cardiovascular Training: Bridging Global Disparities and Building a Hybrid Model for Equity in Care.

Current problems in cardiology·2026
Same journal

Diagnostic and prognostic value of coronary computed tomography angiography and high-risk plaque assessment in acute coronary syndrome.

Current problems in cardiology·2026
Same journal

Prognostic value of albuminuria in heart failure with preserved ejection fraction: A systematic review.

Current problems in cardiology·2026
See all related articles

Related Experiment Video

Updated: Oct 24, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K

Structural Heart Interventions During COVID-19.

Koyenum Obi1, Harith Baldawi1, Shamaki Garba2

  • 1Department of Internal Medicine, Ochsner Medical Center, New Orleans, LA.

Current Problems in Cardiology
|August 13, 2021
PubMed
Summary
This summary is machine-generated.

The COVID-19 pandemic led to the postponement of crucial cardiac procedures like TAVR and LAAC. New guidelines now support safely resuming these advanced interventions for high-acuity patients.

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.8K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

954

Related Experiment Videos

Last Updated: Oct 24, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.8K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

954

Area of Science:

  • Cardiovascular Medicine
  • Public Health Policy
  • Infectious Diseases

Background:

  • The COVID-19 pandemic necessitated resource conservation and public protection, leading to widespread postponement of non-emergent cardiac procedures.
  • Procedures such as transaortic valve replacement (TAVR), left atrial appendage closure (LAAC), MitraClip, and CardioMEMS were significantly impacted by these policies.
  • Initial guidelines were based on the potential for adverse clinical outcomes during the pandemic's peak.

Purpose of the Study:

  • To review updated guidelines from major cardiovascular societies regarding cardiac procedures during the COVID-19 era.
  • To discuss strategies for the safe continuation of advanced cardiac interventions.
  • To improve clinical outcomes for high-acuity patients requiring these procedures amidst the pandemic.

Main Methods:

  • Review of published guidelines from leading cardiovascular societies.
  • Analysis of evolving understanding of SARS-CoV-2 transmission and management.
  • Discussion of logistical and clinical coordination strategies for procedural safety.

Main Results:

  • Cardiovascular societies have issued new guidelines allowing for the careful resumption of advanced cardiac procedures.
  • Enhanced coordination and adherence to safety protocols enable safe performance of TAVR, LAAC, MitraClip, and CardioMEMS.
  • The focus is on balancing procedural necessity with infection control measures.

Conclusions:

  • Advanced cardiac procedures can be safely performed during the COVID-19 pandemic with appropriate planning and adherence to updated guidelines.
  • Careful coordination is essential to mitigate risks and ensure optimal patient outcomes.
  • The resumption of these procedures is critical for managing high-acuity cardiovascular conditions.